Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
List view / Grid view
Researchers have screened over 2,000 compounds to discover that rocaglates effectively combat C. auris, offering a potential new treatment.
International collaboration has shown that compounds with metals in them show antibacterial activity against MRSA, E. coli and A. baumannii.
20 June 2016 | By Victoria White, Digital Content producer
F2G Ltd has raised $60 million in financing to develop its pipeline of novel therapies to treat life threatening invasive fungal infections...
16 February 2016 | By Victoria White
MGB Biopharma and the University of Strathclyde are to extend their existing collaboration to develop novel MGB anti-infectives...
11 May 2015 | By Victoria White
Cidara Therapeutics has announced that the FDA has designated the Company’s lead antifungal product candidate, CD101 IV, as a QIDP with Fast Track status...